What question did this study set out to answer?

Evaluate the impact of cytomegalovirus reactivation on clinical outcomes and survival in allo-HSCT recipients.

Assessing the significance of cytomegalovirus reactivation in recipients of allogeneic hematopoietic stem cell transplantation: a cohort study

View Full Paper

Ask AI

Bookmark

Authors

Cohort study assesses CMV reactivation impact on outcomes in allo-HSCT recipients, suggesting risk factors influence complications.

Evaluate the impact of cytomegalovirus reactivation on clinical outcomes and survival in allo-HSCT recipients.
Retrospective observational cohort study of 67 allo-HSCT recipients
Data collection on clinical, laboratory, and procedural aspects
Assessment of risk factors for CMV reactivation
CMV reactivation occurred in 62.7% of recipients
Median time to CMV reactivation was 32.5 days
One-year overall survival was 57.7%, but no significant relation to mortality after adjustments.

Oliveira et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark